Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD)

Related Clinical Trial
Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy and Metachromatic Leukodystrophy SMART-ALD – A New Lifestyle Intervention to Improve Quality of Life in Women With X-linked Adrenoleukodystrophy (X-ALD) Quality of Life in Women With X-linked Adrenoleukodystrophy A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) Plasma Exchange With Albumin in AMN Patients Stem Cell Transplant for Inborn Errors of Metabolism Human Placental-Derived Stem Cell Transplantation Precision Exercise in Children With Malignant Hemopathies Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy MD1003-AMN MD1003 in Adrenomyeloneuropathy A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients. Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD) A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children Early Diagnosis Of Childhood Cerebral ALD Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children HSCT for High Risk Inherited Inborn Errors Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD) UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD) A Phase III Trial of Lorenzo’s Oil in Adrenomyeloneuropathy Lentiviral Gene Therapy for X-ALD MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD) Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) Newborn Screening for Adrenoleukodystrophy A Study to Prospectively Assess Disease Progression in Male Children With X-ALD Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy Expanded Access for Lorenzo’s Oil (GTO/GTE) in Adrenoleukodystrophy Minnesota Adrenoleukodystrophy Registry Study (MARS) and Biobank A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy

Brief Title

Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD)

Official Title

Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD)

Brief Summary

      The Peroxisome Biogenesis Disorders (PBD) are a group of inherited disorders due to defects
      in peroxisome assembly causing complex developmental and metabolic sequelae. In spite of
      advancements in peroxisome biology, the pathophysiology remains unknown, the spectrum of
      phenotypes poorly characterized and the natural history not yet systematically reported. Our
      aims are to further define this population clinically, biochemically and genetically. The
      investigators will prospectively follow patients from Canada, the US and internationally, and
      collect data from medical evaluations, blood, urine and imaging studies that would be
      performed on a clinical care basis. For patients who are unable to attend our clinic, we will
      collect all medical records and images since birth as well as subsequent records/images for
      the next 5 years or until the end of the study. Clinical data from medical records will be
      banked in our Peroxisomal Disorder Research Databank and Biobank. The investigators will use
      this information to identify standards of care and improve management.

Detailed Description

      Participants have the option to be seen in consultation at the McGill University Health
      Centre in Montreal, Canada, on a yearly basis. This includes a consultation in Genetics,
      Nutrition, Neurology, and Ophthalmology (OCT and FAF exams). All medical records and images
      will be collected, retrospectively and prospectively, until the end of the study, and entered
      anonymously in a database. Biospecimens will be collected to identify new biomarkers.
      Candidate drugs will be evaluated for recovery of peroxisome functions in cultured

Study Type


Primary Outcome

Documentation of the clinical findings

Secondary Outcome

 Peroxisome function testing


Peroxisome Biogenesis Disorder

Study Arms / Comparison Groups

 Patients diagnosed with PBD
Description:  Collection of medical records and images (ultrasounds, X-rays, MRIs, CT scans, ophthalmic images), Next-generation panel, Drug screening, and Consultation


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

January 2012

Completion Date

January 2022

Primary Completion Date

January 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Diagnosis of PBD or

          -  Single peroxisome enzyme/protein defect with phenotype similar to PBD

        Exclusion Criteria:

          -  Not a PBD

          -  Not a single peroxisome enzyme/protein defect with phenotype similar to PBD




N/A - N/A

Accepts Healthy Volunteers



Nancy E Braverman, MD, MS, (1) 514-934-1934, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Study Sponsor

Nancy E Braverman, MD, MS, Principal Investigator, McGill University Health Center, Montreal Childrens Hopital

Verification Date

November 2020